These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36001399)

  • 1. Investigating the effects of age, IQ, dosing, and anthropometric measures on the treatment persistence in long-term methylphenidate use.
    Tuncturk M; Ermis C; Buyuktaskin D; Halac E; Sut E; Ozkan O; Gundogan N; Unutmaz G; Ciray RO; Turan S; Pekcanlar AA
    Nord J Psychiatry; 2023 May; 77(4):345-351. PubMed ID: 36001399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L; Zhou P; Zhu L; Zhang Y; Yang T; Zhao Q; Chen J; Li T; Cheng Q; Chen L
    Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
    Díez-Suárez A; Vallejo-Valdivielso M; Marín-Méndez JJ; de Castro-Manglano P; Soutullo CA
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):723-730. PubMed ID: 28817309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
    Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
    Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status.
    Huang YS; Wang LJ; Chen CK
    BMC Psychiatry; 2012 Nov; 12():194. PubMed ID: 23140464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
    Chen VC; Yang YH; Yu Kuo T; Lu ML; Tseng WT; Hou TY; Yeh JY; Lee CT; Chen YL; Lee MJ; Dewey ME; Gossop M
    Epidemiol Psychiatr Sci; 2020 Jul; 29():e146. PubMed ID: 32686635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder.
    Tsai CS; Huang YS; Wu CL; Hwang FM; Young KB; Tsai MH; Chu SM
    BMC Psychiatry; 2013 Dec; 13():330. PubMed ID: 24305033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Rösler M; Fischer R; Ammer R; Ose C; Retz W
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
    [No Abstract]   [Full Text] [Related]  

  • 14. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
    Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
    PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review.
    Kim HW; Kim SO; Shon S; Lee JS; Lee HJ; Choi JH
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):448-53. PubMed ID: 25285915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).
    McCarthy S; Neubert A; Man KKC; Banaschewski T; Buitelaar J; Carucci S; Coghill D; Danckaerts M; Falissard B; Garas P; Häge A; Hollis C; Inglis S; Kovshoff H; Liddle E; Mechler K; Nagy P; Rosenthal E; Schlack R; Sonuga-Barke E; Zuddas A; Wong ICK
    BMC Psychiatry; 2018 Oct; 18(1):327. PubMed ID: 30305167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
    Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
    JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.